Introduction: Why Does the Scientific Community and B2B Procurement Channel Still Favor Liraglutide API in the "Golden Age" of Weight Loss Pharmaceuticals?
In the rapidly evolving metabolic and biopharmaceutical landscape, Liraglutide API remains a foundation for global generic formulation development and clinical research. Backed by over fifteen years of robust clinical verification, complete pharmacokinetics/pharmacodynamics (PK/PD) characterization, and established global regulatory approvals, it offers a predictable, highly dependable safety profile that emerging experimental compounds cannot yet match.
Liraglutide API Technical & Chemical Specifications
| Product Name | Liraglutide API (USP/EP/CP Grade) |
| CAS Number | 204656-20-2 |
| Molecular Formula | C172H265N43O51 |
| Molecular Weight | 3751.20 g/mol |
| Peptide Sequence | H-HAEGTFTSDVSSYLEGQAAK[γ-Glu-C16]EFIAWLVRGRG-OH |
| Purity (HPLC) | ≥ 99.0% (Single Impurity ≤ 0.5%) |
| Appearance | White to off-white lyophilized powder |
| Solubility | Sparingly soluble in PBS (pH 7.2), soluble in aqueous buffers |
| Counter Ion | Acetate (Standard salt form, custom options available) |
| Trifluoroacetic Acid (TFA) | ≤ 1.0% |
| Water Content (Karl Fischer) | ≤ 5.0% |
| Standard Packaging | 1g, 10g, 50g, 100g, 500g, 1kg (in vacuum-sealed aluminum foil bags) |
How Does Liraglutide API Achieve Significant Weight Loss via "Multi-Dimensional Targeting"?
For research laboratories, generic formulators, and pharmaceutical manufacturers, Liraglutide functions as a precision molecular metabolic agonist. It recalibrates the body’s endogenous glucose-dependent pathways through three targeted physiological mechanisms:
1. How Does it Precisely Modulate the Brain's Satiety Center?
Engineered with a C16 palmitoyl fatty acid side chain, Liraglutide crosses the blood-brain barrier to bind selectively with GLP-1 receptors in the arcuate nucleus of the hypothalamus. High-purity API ensures the complete absence of truncated peptide sequences or acylation isomers. This structural integrity avoids competitive receptor binding, ensuring precise satiety signaling and a reduction in excessive food cravings without triggering localized immunogenic responses.
2. Why is Delayed Gastric Emptying a Critical Physiological Mechanism?
Liraglutide slows the gastric emptying rate, prolonging intestinal nutrient exposure and triggering continuous fullness signals from gastric stretch receptors. To achieve this consistent effect, the peptide must maintain robust conformational stability. Our advanced Solid-Phase Peptide Synthesis (SPPS) and precise cleavage protocols guarantee standard bio-potency, matching the reference listed drug (RLD) to provide predictable clinical formulation outcomes.
3. How Does High-Purity Liraglutide Optimize Lipid Metabolism?
Liraglutide enhances peripheral insulin sensitivity and shifts metabolic prioritization toward fat oxidation while preserving skeletal muscle mass. In low-grade APIs, the presence of oxidized degradation products (especially at Tryptophan and Methionine residues) can accelerate peptide aggregation. Shaanxi Sunrise's ultra-pure API prevents oxidation during storage, protecting metabolic signaling pathways in the finished dosage form.
Why is API Purity (≥ 99.0%) the Non-Negotiable "Red Line" for Safety?
4. Can High Purity Effectively Reduce Gastrointestinal Side Effects?
Residual solvents, process impurities, and high Trifluoroacetic acid (TFA) content in low-grade peptide APIs are known mucosal irritants that exacerbate GI side effects such as nausea, vomiting, and diarrhea. Shaanxi Sunrise's strict purification process limits TFA residues to ≤ 1.0% (successfully converting them into biocompatible acetate salts) and minimizes organic volatile impurities in strict accordance with ICH Q3C guidelines.
5. Why is Reconstitution Stability Critical for Pharmaceutical Manufacturing?
Lower-purity peptide powders are highly prone to fibrillation—forming insoluble beta-sheet aggregates and micro-clumps during reconstitution. Our optimized freeze-drying (lyophilization) cycle ensures an amorphous powder that dissolves rapidly and remains perfectly clear, preserving dosing consistency and mitigating the risk of Anti-Drug Antibody (ADA) development in finished liquid formulations.
What is the "Commercial Moat" of Liraglutide API in Global B2B Biopharma Trade?
6. Why is it a "Safe Haven" for Mitigating R&D and Regulatory Risks?
Entering clinical development or formulating a generic metabolic drug requires a clear developmental path. With fully characterized PK/PD profiles and a long clinical track record, Liraglutide offers the lowest-risk entry point for generic pharmaceutical firms. Shaanxi Sunrise supports your pipeline with comprehensive structural elucidation data, including Mass Spectrometry (MS), HPLC, and stability study packages.
7. How Does High-Purity API Accelerate International Regulatory Approval?
Starting pharmaceutical development with a highly characterized, pure raw material directly aligns with Quality by Design (QbD) principles. Shaanxi Sunrise’s Liraglutide API is backed by a comprehensive CMC (Chemistry, Manufacturing, and Controls) data package, facilitating seamless integration into US DMF (Drug Master File), European CEP, and other international regulatory dossiers to accelerate your product’s timeline to market.
Why Partner with Shaanxi Sunrise Pharmaceutical Co., Ltd. for Liraglutide API?
Precision Peptide Synthesis: Utilizing advanced Solid-Phase Peptide Synthesis (SPPS) technology to ensure 100% correct amino acid sequence alignment and acylation.
Rigorous Analytical Quality Control: Every batch is extensively verified by high-performance liquid chromatography (HPLC) and LC-MS for purity, molecular weight, and structural identity confirmation.
World-Class Manufacturing Infrastructure: Produced in our state-of-the-art GMP-compliant manufacturing facility under strict cleanroom conditions.
Scientist-to-Scientist Support: Our dedicated technical team provides professional guidance on peptide solubility, pH-sensitive stability, and formulation optimization.
1. New England Journal of Medicine (NEJM): Liraglutide for Weight Management in Adults with Obesity - https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
2. Nature Reviews Endocrinology: Pharmacological Mechanisms of GLP-1 Receptor Agonists - https://www.nature.com/nrendo/
3. U.S. Food and Drug Administration (FDA): Official Liraglutide Drug Labeling and Approval Data - https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf